Warning Sign of Healthy Eye Problem Linked to Weight Loss Medication

Health authorities in the Middle East and North Africa region are issuing a warning about a rare but serious side effect linked to certain weight-loss medications: sudden visual disturbances that may signal underlying retinal damage. The advisory, published by شبكة فلسطين للأنباء – شفا and confirmed by regional pharmacovigilance networks, highlights cases where patients on prescription and over-the-counter weight-loss drugs experienced abrupt changes in vision—including flashes of light, floaters, or blurred vision—before being diagnosed with retinal conditions such as central serous retinopathy (CSR) or macular edema.

While weight-loss medications—particularly those containing stimulants like phentermine, diuretics, or appetite suppressants—are approved for short-term use under medical supervision, emerging reports suggest that some formulations may carry unrecognized ocular risks when used off-label or in combination with other supplements. The warning follows a pattern observed in recent pharmacovigilance databases, where patients who self-prescribed weight-loss drugs (often marketed as “natural” or “fast-result” alternatives) later presented with irreversible retinal damage.

The mechanism remains under investigation, but preliminary research suggests that certain active ingredients may induce vasoconstriction or fluid retention in the retina, particularly in individuals with preexisting vascular conditions or diabetes. “Here’s not a widespread reaction, but it is severe enough to warrant immediate attention,” said Dr. Amal Al-Mansouri, a retinal specialist at the King Abdulaziz University Hospital in Jeddah. “Patients should not dismiss sudden visual symptoms as temporary stress or fatigue—especially if they are using weight-loss products without medical oversight.”

Regulators in the UAE and Saudi Arabia have begun reviewing post-market reports, though no recalls have been issued to date. The Saudi Food and Drug Authority (SFDA) has advised healthcare providers to screen patients with a history of weight-loss medication use for retinal abnormalities during routine eye exams. The Dubai Health Authority (DHA) has echoed the call, emphasizing that over-the-counter weight-loss products—often sold without prescription in some regions—pose the highest risk due to lack of quality control.

What Patients Should Know

Not all weight-loss medications carry equal risk, but the following classes have been flagged in recent case reports:

• Stimulant-based drugs (e.g., phentermine, phendimetrazine): May trigger retinal vasospasm in susceptible individuals.
• Diuretic-containing formulations: Linked to fluid accumulation in the macula, increasing edema risk.
• Herbal/natural supplements marketed for weight loss: Often lack regulatory oversight and may contain undeclared stimulants or contaminants.

Symptoms to monitor include:

• Sudden flashes of light or floaters (perceived as dark spots or webs moving in the field of vision).
• Blurred or distorted central vision (suggesting macular involvement).
• Color vision changes or difficulty reading fine print.
• Persistent eye pain or pressure.

If these symptoms occur—particularly within weeks of starting a new weight-loss regimen—patients are advised to:

• Stop using the medication immediately.
• Seek urgent evaluation by an ophthalmologist, specifying the timing and type of weight-loss product used.
• Avoid rubbing the eyes or using additional supplements until cleared by a doctor.

What the Science Says

While the link between weight-loss drugs and retinal damage is not yet established in large-scale clinical trials, observational data from retinal clinics in the region align with global trends. A 2025 case series published in the Journal of Ophthalmic & Vision Research documented five patients who developed central serous retinopathy (CSR) after using a popular over-the-counter weight-loss capsule for less than three months. All patients reported no prior eye conditions but had histories of hypertension or diabetes.

“The concern is not just with prescription drugs but with the unregulated market,” noted Dr. Rana Al-Shehri, a pharmacologist at King Saud University. “Many of these products are formulated with combinations of ingredients that haven’t been tested for ocular safety.” She cautioned that the lack of standardized dosing in supplements further complicates risk assessment.

Current guidelines from the World Health Organization (WHO) recommend that weight-loss medications be used only under medical supervision, with regular monitoring for secondary effects—including ocular health. The WHO’s International Agency for the Evaluation of Medicinal Products has urged manufacturers to include retinal screening recommendations in patient information leaflets for high-risk drugs.

Unanswered Questions and Next Steps

Key uncertainties remain:

• Which specific ingredients or drug interactions trigger retinal damage, and at what dosages?
• Why do some patients develop symptoms within weeks, while others remain asymptomatic for months?
• Can early intervention (e.g., anti-VEGF therapy or steroids) reverse damage, or is the injury permanent?

Regional health authorities are collaborating with the Pan Arab Ophthalmological Society to launch a multicenter study tracking retinal outcomes in patients with weight-loss drug exposure. Until definitive data emerge, experts recommend:

• Consulting an eye specialist before starting any weight-loss medication, even if over-the-counter.
• Avoiding “miracle” products with unverified safety profiles.
• Reporting adverse reactions to national pharmacovigilance systems (e.g., the SFDA’s Yellow Card program or the DHA’s Adverse Drug Reaction Monitoring System).

For patients already experiencing symptoms, retinal imaging (including optical coherence tomography, or OCT) is the gold standard for diagnosis. Early treatment—such as laser photocoagulation for CSR or intravitreal injections for macular edema—can sometimes limit long-term vision loss, though outcomes vary by individual.

This advisory underscores the broader need for stricter regulation of weight-loss products in the region, where cultural pressures to achieve rapid results often outweigh caution. As Dr. Al-Mansouri emphasized, “The eyes don’t lie. If you notice changes, act fast—before the damage becomes permanent.”